Compare CRWS & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | JSPR |
|---|---|---|
| Founded | 1957 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Textiles | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 24.4M |
| IPO Year | 1994 | N/A |
| Metric | CRWS | JSPR |
|---|---|---|
| Price | $2.77 | $0.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 19.4K | ★ 218.6K |
| Earning Date | 02-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 11.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.51 | N/A |
| 52 Week Low | $2.35 | $0.62 |
| 52 Week High | $3.38 | $7.19 |
| Indicator | CRWS | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 49.02 |
| Support Level | $2.72 | $0.81 |
| Resistance Level | $2.87 | $1.03 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 27.79 | 54.61 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.